Semaglutide and cardiovascular outcomes: who was actually

“Reduces cardiovascular risk” needs a population and an outcome attached to it. A trial in people with established cardiovascular disease answers a different question from a trial in people with diabetes and kidney disease. It also differs from research measuring weight, cholesterol or a predicted risk score. Reading those distinctions prevents a genuine finding from becoming an overly broad claim.

SELECT: obesity or overweight with established disease

SELECT studied 17,604 adults aged at least 45 with established cardiovascular disease, a body-mass index of at least 27 and no diabetes. Weekly injected semaglutide 2.4 mg was compared with placebo. The primary composite counted cardiovascular death, nonfatal heart attack or nonfatal stroke. Events occurred in 6.5% versus 8.0%; the reported hazard ratio was 0.80 over a mean 39.8 months of follow-up.

A hazard ratio of 0.80 describes a relative comparison over follow-up. It is not a reduction of 20 percentage points in the chance of an event. The observed event percentages give another view of the result. Neither statistic supplies a personalized risk estimate for someone whose age, history or background treatment differs from the trial.

SOUL: oral treatment in high-risk type 2 diabetes

SOUL enrolled adults aged at least 50 with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both. It tested oral semaglutide against placebo on top of standard care. The primary cardiovascular composite was lower with oral semaglutide. That finding concerns a different clinical population and oral regimen from SELECT; the trial names should not be used interchangeably.

Four claims that require different evidence

Claim	Evidence to look for
Fewer cardiovascular events	A trial that counted those events in a defined population.
Improved risk factors	Measurements such as blood pressure, with their own analysis.
Lower predicted risk	A prediction model, distinct from observed future events.
An approved indication	The current label for the exact product and route.

Approval and trial design are separate layers

The current Wegovy label includes cardiovascular risk reduction for specified adults with established cardiovascular disease and obesity or overweight, including a tablet formulation. That does not turn SELECT itself into an oral-tablet trial: SELECT used injections. A careful page should state both the current product authorization and the original research design without rewriting either to make them appear identical.

Likewise, a diabetes-focused cardiovascular study should not be presented as proof of benefit for every person seeking weight loss. Established disease, kidney function, diabetes status and other therapies can change the clinical question. The responsible next step is to identify the treatment objective and have the clinician explain which evidence supports the proposed product for that objective.

A consultation note worth keeping

Record the exact outcome being discussed, your relevant diagnoses and the label or paper used to support the recommendation. Ask how the medicine fits with the rest of cardiovascular care and what follow-up will assess. Ask separately about weight goals, because success on one measure does not automatically establish success on another. A precise conversation can acknowledge meaningful cardiovascular evidence while keeping its limits visible.

When revisiting the decision, use the same outcome definitions. Changes in how you feel, a scale reading and a prevented cardiovascular event are different kinds of information. Clear definitions make long-term review more useful than a general promise about protecting the heart.

Sources and reading scope

Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.